Pancreatic ductal adenocarcinoma is a highly desmoplastic tumour, and non-malignant stromal cells contribute to progression and treatment resistance. Inflammatory cells in particular are known drivers of carcinogenesis, and macrophages are one of the most abundant inflammatory leucocytes. Therefore, exploring how macrophages drive tumour progression in pancreatic cancer would not only aid in understanding disease biology but could also offer insight to novel treatment strategies. Results presented in this thesis show macrophages secrete factors that drive epithelial-to-mesenchymal transition, promote invasion and lead to expression of checkpoint inhibitors. To determine what factors were driving this phenotype, the serine protease inhibitor SerpinB3 was initially explored, as it was highly upregulated in cancer cells cultured with conditioned media from macrophages. However, SerpinB3 gene overexpression and knockdown did not confirm a direct role for this gene in mediating migration and invasion. Further investigation revealed macrophages were secreting the cytokine oncostatin M, which was driving a metastatic phenotype through activation of the STAT3 pathway. Expression of oncostatin M receptor was upregulated in cancer cells following culture with macrophage conditioned media and conferred a worse prognosis in patient samples. STAT3 pathway activation by oncostatin M led to increased invasion in vitro, particularly of the highly tumourigenic cancer stem cell population, and increased metastasis in vivo. Moreover, oncostatin M mediated expression of the immune 'checkpoint' inhibitors on the surface of pancreatic cancer cells. Using antibody and small molecule inhibitors, reversion of these signalling pathway effects were seen and preliminary data from in vivo assays showed decreased metastasis formation with cytokine receptor antibody inhibition. Overall, the findings in this thesis contribute to emerging knowledge of how tumour associated macrophages drive tumour progression in pancreatic adenocarcinoma. Not only do they promote invasion and metastatic potential through oncostatin M secretion, but also potentiate inherent biological properties of cancer stem cells and assist in immune tolerance. In addition, results provide preliminary data to support a rationale for clinical targeting of macrophage-derived oncostatin M in pancreatic cancer.

Pancreatic cancer is the fourth leading cause of cancer death in the United States, with a five-year survival rate under 5%. Given the disease’s deadliness, increasing our understanding of the molecular nature of the pancreatic cancer is key to developing more effective preventive measures and treatments. Dietary energy restriction (DER) has been shown to have potent anticancer effects in pancreatic cancer, but the mechanism of action has yet to be completely elucidated. Here we investigate the potential of altered microRNA expression as a mechanism by which DER exerts its anticancer effect. Using the Exiqon microRNA Array, we identified several microRNAs of interest for further study. This includes microRNA (mir) 669c, a known regulator of glutathione-S transferases (linked to carcinogen metabolism and oxidative stress) that increases with age. To our knowledge, this is the first exploration of the effects of DER (which is known to suppress oxidative stress and other processes associated with aging and cancer) on microRNA expression. These findings may provide the initial steps towards identifying novel targets for pancreatic cancer prevention or treatment. / text

Pancreatic cancer (PC) is known to be highly resistant to chemotherapy. Transporters, which regulate the influx and efflux of substrates across the plasma membrane, may play a role in PC drug resistance. ABC transporters are a large family of transmembrane proteins with diverse physiological functions, several of which play major roles in cancer drug resistance. Given that 90% of PC express a mutant K-ras oncogene and that PC are highly hypoxic, I postulated that constitutive K-ras activation and/or hypoxia may correlate with ABC transporter expression, which in turn may promote drug resistance in PC. Using normal and PC cell lines either overexpressing mutant K-ras or subjected to hypoxic treatment, mRNA expression was profiled for 48 ABC transporters. My findings indicate that expression of mutant K-ras and hypoxic treatment, as well as long-term exposure to chemotherapy, may contribute to the development of drug resistance in PC cells in part by inducing the expression of ABC transporters. Similar to ABC transporters, I investigated whether amino acid transporters would mediate drug resistance in PC. The Xc⁻ amino acid transporter (Xc⁻) mediates cellular uptake of cystine for the biosynthesis of glutathione, a major detoxifying agent. Because the Xc⁻ has been regulates the growth of various cancer cell types, and Xc⁻ is expressed in the pancreas, I postulated that the Xc⁻ may be involved in growth and drug resistance in PC. The Xc⁻ transporter is differentially expressed in normal pancreatic tissues and is overexpressed in PC in vivo. Using PC cell lines, I found that cystine uptake via the Xc⁻ was required for growth and survival in response to oxidative stress, and that expression of the Xc⁻ correlated with gemcitabine resistance. Accordingly, inhibition of Xc⁻ expression via siRNA reduced PC cell proliferation and restored sensitivity to gemcitabine. I also identified the anti-inflammatory drug sulfasalazine as a mixed inhibitor of the Xc⁻, which acts to inhibit cell proliferation via reducing Xc⁻ activity and not by reducing NFKB activity. My findings thus indicate that the Xc⁻ plays a role in PC growth in partby contributing to glutathione synthesis to promote PC cell proliferation, survival, and drug resistance.

No description available.

Pancreatic cancer (PC) is known to be highly resistant to chemotherapy. Transporters, which regulate the influx and efflux of substrates across the plasma membrane, may play a role in PC drug resistance. ABC transporters are a large family of transmembrane proteins with diverse physiological functions, several of which play major roles in cancer drug resistance. Given that 90% of PC express a mutant K-ras oncogene and that PC are highly hypoxic, I postulated that constitutive K-ras activation and/or hypoxia may correlate with ABC transporter expression, which in turn may promote drug resistance in PC. Using normal and PC cell lines either overexpressing mutant K-ras or subjected to hypoxic treatment, mRNA expression was profiled for 48 ABC transporters. My findings indicate that expression of mutant K-ras and hypoxic treatment, as well as long-term exposure to chemotherapy, may contribute to the development of drug resistance in PC cells in part by inducing the expression of ABC transporters. Similar to ABC transporters, I investigated whether amino acid transporters would mediate drug resistance in PC. The Xc⁻ amino acid transporter (Xc⁻) mediates cellular uptake of cystine for the biosynthesis of glutathione, a major detoxifying agent. Because the Xc⁻ has been regulates the growth of various cancer cell types, and Xc⁻ is expressed in the pancreas, I postulated that the Xc⁻ may be involved in growth and drug resistance in PC. The Xc⁻ transporter is differentially expressed in normal pancreatic tissues and is overexpressed in PC in vivo. Using PC cell lines, I found that cystine uptake via the Xc⁻ was required for growth and survival in response to oxidative stress, and that expression of the Xc⁻ correlated with gemcitabine resistance. Accordingly, inhibition of Xc⁻ expression via siRNA reduced PC cell proliferation and restored sensitivity to gemcitabine. I also identified the anti-inflammatory drug sulfasalazine as a mixed inhibitor of the Xc⁻, which acts to inhibit cell proliferation via reducing Xc⁻ activity and not by reducing NFKB activity. My findings thus indicate that the Xc⁻ plays a role in PC growth in partby contributing to glutathione synthesis to promote PC cell proliferation, survival, and drug resistance.

Thesis (Ph. D.)--Ohio State University, 2005. / Title from first page of PDF file. Document formatted into pages; contains xxiv, 185 p.; also includes graphics. Includes bibliographical references (p. 164-185). Available online via OhioLINK's ETD Center

Thesis (Ph. D.)--University of Louisville, 2004. / Department of Pharmacology and Toxicology. Vita. "August 2004." Includes bibliographical references (leaves 124-142).

Pancreatic cancer (PC) is known to be highly resistant to chemotherapy. Transporters, which regulate the influx and efflux of substrates across the plasma membrane, may play a role in PC drug resistance. ABC transporters are a large family of transmembrane proteins with diverse physiological functions, several of which play major roles in cancer drug resistance. Given that 90% of PC express a mutant K-ras oncogene and that PC are highly hypoxic, I postulated that constitutive K-ras activation and/or hypoxia may correlate with ABC transporter expression, which in turn may promote drug resistance in PC. Using normal and PC cell lines either overexpressing mutant K-ras or subjected to hypoxic treatment, mRNA expression was profiled for 48 ABC transporters. My findings indicate that expression of mutant K-ras and hypoxic treatment, as well as long-term exposure to chemotherapy, may contribute to the development of drug resistance in PC cells in part by inducing the expression of ABC transporters. Similar to ABC transporters, I investigated whether amino acid transporters would mediate drug resistance in PC. The Xc⁻ amino acid transporter (Xc⁻) mediates cellular uptake of cystine for the biosynthesis of glutathione, a major detoxifying agent. Because the Xc⁻ has been regulates the growth of various cancer cell types, and Xc⁻ is expressed in the pancreas, I postulated that the Xc⁻ may be involved in growth and drug resistance in PC. The Xc⁻ transporter is differentially expressed in normal pancreatic tissues and is overexpressed in PC in vivo. Using PC cell lines, I found that cystine uptake via the Xc⁻ was required for growth and survival in response to oxidative stress, and that expression of the Xc⁻ correlated with gemcitabine resistance. Accordingly, inhibition of Xc⁻ expression via siRNA reduced PC cell proliferation and restored sensitivity to gemcitabine. I also identified the anti-inflammatory drug sulfasalazine as a mixed inhibitor of the Xc⁻, which acts to inhibit cell proliferation via reducing Xc⁻ activity and not by reducing NFKB activity. My findings thus indicate that the Xc⁻ plays a role in PC growth in partby contributing to glutathione synthesis to promote PC cell proliferation, survival, and drug resistance. / Medicine, Faculty of / Medicine, Department of / Experimental Medicine, Division of / Graduate

Pancreatic Ductal Adenocarcinoma (PDA) is one of the most lethal solid malignancies primarily because it is staunchly resistant to conventional cytotoxic chemotherapies. Xenograft models are typically not sophisticated enough to reproduce the complex pathophysiology of the clinical disease. This is the main reason why treatments that have shown promise in preclinical mouse models have not translated into improvements in median survival in the clinic. Genetically engineered KPC mice develop PDA in situ which recapitulates the genetic, molecular and pathophysiological features of human PDA. Spontaneous KPC tumours are also chemoresistant and this mouse model therefore provides an ideal platform from which to study the biology of PDA. Recent evidence suggests that poor perfusion and extensive fibrosis may prevent the delivery of cytotoxic agents to neoplastic PDA cells and are therefore at least in part responsible for the chemoresistance demonstrated by human PDA tumours and spontaneous KPC tumours. In this thesis we use non-invasive Magnetic Resonance Imaging techniques (Dynamic ContrastEnhanced (DCE-) MRI, Magnetisation Transfer Imaging (MTI)) and SHG microscopy to evaluate the perfusion properties and fibrosis of three different mouse models of PDA: spontaneous KPC tumours, allografts initiated by transplantation of pancreatic tumour cells derived from a KPC tumour, and allografts initiated by co-transplantation of these cells with pancreatic stellate cells (fibrotic allografts). Using DCE-MRI and MTI we showed that the perfusion of spontaneous KPC tumours and fibrotic allografts decreases with increasing tumour volume while the tumour macromolecular content increases with increasing tumour volume. This is in contrast to the viable portion of non-fibrotic allografts which have a low macromolecular content and exhibit sustained moderate perfusion irrespective of tumour volume. Ex viva SHG microscopy clearly showed differences in the type, distribution and magnitude of fibrosis in these models. Using MTI, we showed a differential between spontaneous and transplanted tumours, but not between fibrotic and non-fibrotic allografts. We subsequently investigated the ability of MTI to detect treatment-induced depletion of the stroma in spontaneous KPC tumours, to assess its possible application as a non-invasive biomarker for treatment response in the clinic. However, we were unable to detect such depletion by MTI, although ex viva SHG microscopy confirmed that it did occur. In summary, our results contribute to the body of know_ledge on the biology of PDA and strengthen the evidence that early detection of PDA would be required to improve the chances of effective drug delivery to PDA tumours.

In this study, we searched for significant hypo and hyper methylation CpG (5'-C-phosphate-G-3') probes from The Cancer Genome Atlas (TCGA) datasets. First, the relationship between hypo and hypermethylation pattern in significantly expressed genes associated in pancreatic ductal adenocarcinoma (PDAC) was analyzed using computational methodologies in R package. This was done by combining DNA methylation (DM) and gene expression (GE) information, and their corresponding metadata (i.e., clinical data and molecular subtypes) and saved as R files. Next, examination of differentially methylated CpG sites (DMCs) between two groups (normal vs tumor) was identified gene sets. From this analysis, we found nine (09) overexpressed hypomethylated and six (06) under expressed hypermethylated genes near significant CpG probes. Results from this work will shed light on the relationship between CpG methylation and gene expression associated with PDAC.